Abeona Therapeutics (ABEO) Net Income towards Common Stockholders (2016 - 2025)
Historic Net Income towards Common Stockholders for Abeona Therapeutics (ABEO) over the last 15 years, with Q3 2025 value amounting to -$5.2 million.
- Abeona Therapeutics' Net Income towards Common Stockholders rose 8294.96% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $87.2 million, marking a year-over-year increase of 19491.93%. This contributed to the annual value of -$63.7 million for FY2024, which is 1752.77% down from last year.
- According to the latest figures from Q3 2025, Abeona Therapeutics' Net Income towards Common Stockholders is -$5.2 million, which was up 8294.96% from $113.7 million recorded in Q2 2025.
- In the past 5 years, Abeona Therapeutics' Net Income towards Common Stockholders ranged from a high of $113.7 million in Q2 2025 and a low of -$46.7 million during Q4 2021
- In the last 5 years, Abeona Therapeutics' Net Income towards Common Stockholders had a median value of -$12.0 million in 2025 and averaged -$8.9 million.
- In the last 5 years, Abeona Therapeutics' Net Income towards Common Stockholders crashed by 24725.27% in 2024 and then soared by 94523.35% in 2025.
- Abeona Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$46.7 million in 2021, then skyrocketed by 84.79% to -$7.1 million in 2022, then plummeted by 133.8% to -$16.6 million in 2023, then soared by 44.22% to -$9.3 million in 2024, then soared by 44.26% to -$5.2 million in 2025.
- Its Net Income towards Common Stockholders was -$5.2 million in Q3 2025, compared to $113.7 million in Q2 2025 and -$12.0 million in Q1 2025.